{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T15:51:55Z","timestamp":1773503515023,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.msard.2021.102964","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T23:58:56Z","timestamp":1618963136000},"page":"102964","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Progressive myelopathy in myelin oligodendrocyte glycoprotein antibody-associated disease: A new mimicker of progressive multiple sclerosis?"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6729-0108","authenticated-orcid":false,"given":"Samuel B.","family":"Marcucci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5713-4056","authenticated-orcid":false,"given":"Mohamed","family":"Elkasaby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosemarie","family":"Walch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8332-4179","authenticated-orcid":false,"given":"Ameneh","family":"Zare-Shahabadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdelkader","family":"Mahammedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hesham","family":"Abboud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0424-7460","authenticated-orcid":false,"given":"Aram","family":"Zabeti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2021.102964_bib0001","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1148\/rg.2018170141","article-title":"NeuromyelitisOptica Spectrum Disorders: Spectrum of MR Imaging Findings and Their Differential Diagnosis","volume":"38","author":"Dutra","year":"2018","journal-title":"RadioGraphics"},{"issue":"14","key":"10.1016\/j.msard.2021.102964_bib0002","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1177\/1352458519893093","article-title":"MRI differences between MOG antibody disease and AQP4 NMOSD","volume":"26","author":"Salama","year":"2020","journal-title":"Mult. Scler. J."},{"issue":"2","key":"10.1016\/j.msard.2021.102964_bib0003","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1056\/NEJMoa022328","article-title":"Antimyelin Antibodies as a Predictor of Clinically Definite Multiple Sclerosis after a First Demyelinating Event","volume":"349","author":"Berger","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.msard.2021.102964_bib0004","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/intimm\/dxh056","article-title":"Anti-MOG autoantibodies in Italian multiple sclerosis patients: specificity, sensitivity and clinical association","volume":"16","author":"Mantegazza","year":"2004","journal-title":"Int. Immunol."},{"issue":"1","key":"10.1016\/j.msard.2021.102964_bib0005","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12974-018-1108-6","article-title":"MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature","volume":"15","author":"Jarius","year":"2018","journal-title":"J. Neuroinflamm."},{"issue":"2","key":"10.1016\/j.msard.2021.102964_bib0006","doi-asserted-by":"crossref","first-page":"e649","DOI":"10.1212\/NXI.0000000000000649","article-title":"Frequency of myelin oligodendrocyte glycoprotein antibody in multiple sclerosis","volume":"7","author":"Cobo-Calvo","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.msard.2021.102964_bib0007","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J. Neuroinflamm."},{"issue":"5","key":"10.1016\/j.msard.2021.102964_bib0008","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1212\/NXI.0000000000000257","article-title":"Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis","volume":"3","author":"Spadaro","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"10","key":"10.1016\/j.msard.2021.102964_bib0009","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1007\/s00415-019-09440-8","article-title":"Unilateral cortical FLAIR-hyperintense Lesions in Anti-MOG-associated Encephalitis with Seizures (FLAMES): characterization of a distinct clinico-radiographic syndrome","volume":"266","author":"Budhram","year":"2019","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2021.102964_bib0010","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.msard.2021.102964_bib0011","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1212\/WNL.0000000000009758","article-title":"Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder","volume":"95","author":"Chen","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2021.102964_bib0012","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflamm."},{"issue":"8","key":"10.1016\/j.msard.2021.102964_bib0013","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1177\/1352458514568827","article-title":"Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study","volume":"21","author":"Kuhle","year":"2015","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2021.102964_bib0014","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.msard.2018.09.010","article-title":"Clinical utility of anti-MOG antibody testing in a Danish cohort","volume":"26","author":"Papp","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.102964_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102191","article-title":"A case of myelin oligodendrocyte glycoprotein-antibody-associated disease presenting with tumefactive demyelinating lesion","volume":"43","author":"Ataka","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2021.102964_bib0016","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/acn3.164","article-title":"Histopathology and clinical course of MOG-antibody-associated encephalomyelitis","volume":"2","author":"Spadaro","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2021.102964_bib0017","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1001\/archneur.65.11.1527","article-title":"Persistence of Immunopathological and Radiological Traits in Multiple Sclerosis","volume":"65","author":"K\u00f6nig","year":"2008","journal-title":"Arch. Neurol."},{"issue":"12","key":"10.1016\/j.msard.2021.102964_bib0018","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1177\/1352458515622986","article-title":"Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in \u2018pattern II multiple sclerosis\u2019 and brain biopsy findings in a MOG-IgG-positive case","volume":"22","author":"Jarius","year":"2016","journal-title":"Mult. Scler. J."},{"issue":"4","key":"10.1016\/j.msard.2021.102964_bib0019","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","article-title":"Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody\u2013Associated Disease","volume":"75","author":"Hacohen","year":"2018","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.msard.2021.102964_bib0020","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/1352458520907900","article-title":"Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies","volume":"27","author":"Sechi","year":"2020","journal-title":"Mult. Scler. J."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821002315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821002315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:52:31Z","timestamp":1761900751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821002315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":20,"alternative-id":["S2211034821002315"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.102964","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progressive myelopathy in myelin oligodendrocyte glycoprotein antibody-associated disease: A new mimicker of progressive multiple sclerosis?","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.102964","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102964"}}